表紙
市場調查報告書

原發性硬化性膽管炎治療的全球市場:2018年∼2022年

Global Primary Sclerosing Cholangitis Treatment Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 694202
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
原發性硬化性膽管炎治療的全球市場:2018年∼2022年 Global Primary Sclerosing Cholangitis Treatment Market 2018-2022
出版日期: 2018年08月28日內容資訊: 英文 110 Pages
簡介

關於原發性硬化性膽管炎

原發性硬化性膽管炎是單獨發生或由於其他疾病而發生的慢性肝病。該疾病的特徵在於膽管的炎症和增厚。這會阻礙膽汁流動,從而導致其他肝臟疾病。

Technavio的分析師,預測著從2018年開始在2022年之間,全球原發性硬化性膽管炎治療市場3.57%的年複合成長率成長。

本報告提供全球原發性硬化性膽管炎治療市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 簡介

  • 原發性硬化性膽管炎
  • 市場情形
  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第5章 市場規模

  • 市場定義
  • 市場規模(2017年)
  • 市場規模及預測(2017-2022年)

第6章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情形

第7章 開發平台情勢

第8章 市場區隔:各產品

  • 市場區隔:各產品(2017-2022年)
  • 比較:各產品
  • UDCA
  • 其他
  • 市場機會:各產品

第9章 客戶形勢

第10章 地區形勢

  • 各地區市場區隔(2017-2022年)
  • 地區比較
  • 南北美洲 -
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 市場機會

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

  • 合理價格的PSC治療藥的開發
  • PSC的臨床試驗的替代評估項目
  • PSC治療用siRNA治療藥

第14章 業者情勢

  • 概要
  • 創造性破壞狀況

第15章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • ALLERGAN
  • Glenmark
  • Impax Laboratories
  • Mylan
  • TEVA Pharmaceutical

第16章 附錄

  • 簡稱的清單
目錄
Product Code: IRTNTR23653

About Primary Sclerosing Cholangitis

Primary sclerosing cholangitis is chronic liver disease that can occur either by itself or due to other diseases. The disease is characterized by the inflammation and thickening of the bile ducts. This obstructs bile flow, which may lead to other liver diseases.

Technavio's analysts forecast the Global Primary Sclerosing Cholangitis Treatment Market to grow at a CAGR of 3.57% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the primary sclerosing cholangitis treatment market. To calculate the market size, the report considers the revenue generated from the primary sclerosing cholangitis treatment across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Primary Sclerosing Cholangitis Treatment Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • Glenmark
  • Impax Laboratories
  • Mylan
  • Teva Pharmaceuticals

Market driver

  • Rise in number of liver transplants and UDCA treatment
  • For a full, detailed list, view our report

Market challenge

  • Poor understanding of PSG pathogenesis
  • For a full, detailed list, view our report

Market trend

  • Development of affordable PSC drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Primary sclerosing cholangitis
  • MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • UDCA - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Development of affordable PSC drugs
  • Surrogate endpoints for clinical trials in PSC
  • siRNA therapeutic products for treatment of PSC

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALLERGAN
  • Glenmark
  • Impax Laboratories
  • Mylan
  • TEVA Pharmaceutical

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global metabolic disorder therapeutic market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global - Market size and forecast 2017-2022 ($ mn)
  • Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 09: Five forces analysis 2017
  • Exhibit 10: Five forces analysis 2022
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2017
  • Exhibit 17: Pipeline landscape by development phase
  • Exhibit 18: Key clinical trials candidates of primary sclerosing cholangitis
  • Exhibit 19: Product - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: UDCA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: UDCA - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: Others - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 24: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Global - Market share by geography 2017-2022 (%)
  • Exhibit 28: Regional comparison
  • Exhibit 29: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 30: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 31: Top 3 countries in Americas
  • Exhibit 32: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 33: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 34: Top 3 countries in EMEA
  • Exhibit 35: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 36: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 37: Top 3 countries in APAC
  • Exhibit 38: Market opportunity
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendors covered
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: ALLERGAN - Overview
  • Exhibit 45: ALLERGAN - Business segments
  • Exhibit 46: ALLERGAN - Organizational developments
  • Exhibit 47: ALLERGAN - Geographic focus
  • Exhibit 48: ALLERGAN - Segment focus
  • Exhibit 49: ALLERGAN - Key offerings
  • Exhibit 50: ALLERGAN - Key customers
  • Exhibit 51: Glenmark - Overview
  • Exhibit 52: Glenmark - Business segments
  • Exhibit 53: Glenmark- Organizational developments
  • Exhibit 54: Glenmark - Geographic focus
  • Exhibit 55: Glenmark - Segment focus
  • Exhibit 56: Glenmark - Key offerings
  • Exhibit 57: Glenmark - Key customers
  • Exhibit 58: Impax Laboratories - Overview
  • Exhibit 59: Impax Laboratories - Business segments
  • Exhibit 60: Impax Laboratories - Organizational developments
  • Exhibit 61: Impax Laboratories - Geographic focus
  • Exhibit 62: Impax Laboratories - Segment focus
  • Exhibit 63: Impax Laboratories - Key offerings
  • Exhibit 64: Impax Laboratories - Key customers
  • Exhibit 65: Mylan - Overview
  • Exhibit 66: Mylan - Business segments
  • Exhibit 67: Mylan - Organizational developments
  • Exhibit 68: Mylan - Geographic focus
  • Exhibit 69: Mylan - Segment focus
  • Exhibit 70: Mylan - Key offerings
  • Exhibit 71: Mylan - Key customers
  • Exhibit 72: TEVA Pharmaceutical - Overview
  • Exhibit 73: TEVA Pharmaceutical - Business segments
  • Exhibit 74: TEVA Pharmaceutical - Organizational developments
  • Exhibit 75: TEVA Pharmaceutical - Geographic focus
  • Exhibit 76: TEVA Pharmaceutical - Segment focus
  • Exhibit 77: TEVA Pharmaceutical - Key offerings
  • Exhibit 78: TEVA Pharmaceutical - Key customers